These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 6241560)

  • 21. Hospitalizations among black women using contraceptives.
    Higgins JE; Wilkens LR; Chi IC; Hatcher RA
    Am J Obstet Gynecol; 1985 Oct; 153(3):280-7. PubMed ID: 2931987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study.
    Garza-Flores J; Cardenas S; Rodríguez V; Cravioto MC; Diaz-Sanchez V; Perez-Palacios G
    Contraception; 1985 Apr; 31(4):361-6. PubMed ID: 3159544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
    Knuth UA; Yeung CH; Nieschlag E
    Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained effects on synthetic ovarian steroids of rat myometrial contractility.
    Parkington HC; Lipton A
    J Endocrinol; 1976 Aug; 70(2):223-7. PubMed ID: 965882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of children whose mothers used oral contraceptives prior to conception.
    Magidor S; Palti H; Harlap S; Baras M
    Contraception; 1984 Mar; 29(3):203-14. PubMed ID: 6734207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In utero exposure to steroid contraceptives and outcome of pregnancy.
    Pardthaisong T; Gray RH
    Am J Epidemiol; 1991 Oct; 134(8):795-803. PubMed ID: 1835282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years.
    Frank DW; Kirton KT; Murchison TE; Quinlan WJ; Coleman ME; Gilbertson TJ; Feenstra ES; Kimball FA
    Fertil Steril; 1979 Mar; 31(3):340-6. PubMed ID: 437169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
    Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
    Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of depot-medroxyprogesterone acetate on the fetus and nursing infant: a review.
    Schwallie PC
    Contraception; 1981 Apr; 23(4):375-86. PubMed ID: 6456130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone secretion in idiopathic precocious puberty: effect of medroxyprogesterone.
    Kaplan S; Frasier SD; Costin G
    J Pediatr; 1969 Jul; 75(1):133-8. PubMed ID: 5790396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct effects of medroxyprogesterone acetate (MPA) and megestrol acetate (MGA) on rat testicular steroidogenesis.
    Barbieri RL; Ryan KJ
    Acta Endocrinol (Copenh); 1980 Jul; 94(3):419-25. PubMed ID: 6968496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ; Dullaart J; Zeilmaker GH
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days.
    Siriwongse T; Snidvongs W; Tantayaporn P; Leepipatpaiboon S
    Contraception; 1982 Nov; 26(5):487-93. PubMed ID: 6218964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
    Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
    Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invited commentary: the contraceptive technology tightrope.
    Hogue CJ
    Am J Epidemiol; 1991 Oct; 134(8):812-5; discussion 816-7. PubMed ID: 1835284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levels of contraceptive seroids in breast milk and plasma of lactating women.
    Saxena BN; Shrimanker K; Grudzinskas JG
    Contraception; 1977 Dec; 16(6):605-13. PubMed ID: 606500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.
    Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A
    Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels.
    Frick J; Bartsch G; Weiske WH
    Contraception; 1977 Jun; 15(6):649-68. PubMed ID: 891192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.